|
EDUCATION:
| Post
Doctoral Research Fellow |
NIH
Young Investigator Award, Protein biochemistry,
University of Texas Health Science Center at Houston (1988-1992) |
| Ph.D. |
Rice
Graduate Fellow Award, Molecular and cell biology,
Department of Biochemistry and Cell Biology, Rice University
(1984-1988)
|
| B.S. |
Biology/Chemistry,
Department of Natural and Applied Sciences, University
of Houston at Clear Lake (1979-1984) |
| A.S. |
Biology/Chemistry,
Department of Biology, San Jacinto College, Houston (1976-1978)
|
EXPERIENCE:
CURRENT
POSITION July 2004 to present |
|
Senior
Consultant -
Biologics
Consulting Group, Inc., Germantown, MD.
- Review
client internal policies and SOPs to assess suitability
of their technical and quality practices for product
development activities; prepare gap analysis reports
for existing deficiencies relative to current FDA/ICH
expectations.
- Provide
technical and quality assistance in identity, purity,
potency, and stability test method development, validation,
troubleshooting and OOS investigations for biopharmaceuticals.
- Evaluate
client CMC regulatory strategies for product development
from pre-Phase I to BLA, with emphasis on drug substance
and drug product characterization, comparability assessment,
release and stability testing.
- Prepare
and review client IND and BLA submissions for suitability
relative to current FDA expectations for CMC data
from biotechnological/biological products.
- Develop
and deliver training sessions on technical, regulatory
and quality elements of biological product development.
|
| |
|
|
| Feb.
2004 to July 2004 |
|
Consultant
(Affiliate) -
Biologics
Consulting Group, L.L.C., Germantown, MD.
|
| |
|
|
| 2002
to 2004 |
|
Contractor,
American Red Cross Plasma Derivatives, Rockville, MD.
-
Served as principle CMC RA/QA associate for Plasma
Derivative product development projects.
- Established
and implement R&D quality practice policies ("Good
Development Practices" or "GDP") to
support the development of plasma-derived products
for FDA and international submissions.
- Established
and implement $250K NuGenesis SDMS electronic documentation
system for six product discovery and development laboratories.
- Prepared
internal guidance documents and conduct training sessions
on technical, regulatory and quality elements of biological
product development.
- Prepared
and review FDA IND and BLA submissions for nationally
and internationally manufactured plasma products.
- Participated
in international project teams to plan and execute
regulatory and quality strategies for product development
from Phase I to BLA.
|
| |
|
|
| 2002
to present |
|
Biotechnology
Product Consultant, NMR Biotech, Germantown, MD.
- Provided
expertise on biotechnology product development, laboratory
quality practices, test method validation, product
stability programs, and management of outsourced biopharmaceutical
testing and manufacturing.
- Prepared
and review CMC sections for IND and BLA submissions
for a wide variety of biological and biotechnological
products, participate in IND/BLA meetings with regulators,
and respond to regulatory reviewer questions.
- Conducted
quality audits of US and international facilities
for cGMP and GLP compliance assessment. Design and
review quality system documentation required for laboratory
facilities for R&D, GLP and cGMP.
- Designed
and review protocols for product characterization,
process and test method validation and product stability
programs.
- Presented
seminars and training classes on the technical, regulatory
and quality elements required in biotechnology product
development and commercialization. Serve as subject
matter expert in preparation and review of journal
articles and book chapters.
- Facilitated
professional meetings on biopharmaceutical industry
issues, including interactions among industry and
regulatory bodies.
|
| |
|
|
| 2001
to 2002 |
|
Director
of Technical and Regulatory Affairs, BioReliance
Corporation, Analytical Services Division, Rockville,
MD.
- Served
as the principal point of scientific and regulatory
CMC interaction with over 150 worldwide pharmaceutical
clients for their national and international product
submissions for biotechnology products.
- Provided
expertise on product development requirements for
recombinant proteins, monoclonal antibodies, plasma
products, transgenic proteins, viral vectors, vaccines,
and synthetic biomolecules (e.g. peptides and oligonucleotides).
- Supported
Analytical Division project managers and study directors
to ensure successful design and execution of complex
or custom projects.
- Served
as consultant to clients for technical and regulatory
issues related to the CMC sections of INDs, BLAs,
NDAs, annual reviews and supplements.
- Consulted
internally and externally on quality practices and
compliance issues.
- Developed
and updated corporate Analytical marketing and training
materials.
- Supported
the sales force and other members of the Sales and
Marketing team as Analytical expert for client inquiries.
- Delivered
client presentations, professional seminars and training
classes on biomolecular methods, regulatory product
development guidelines, laboratory management, and
quality/compliance practices.
- Interacted
with regulatory bodies as industry expert and served
as client advocate to regulatory reviewers for product
submissions.
|
| |
|
|
| 1998
to 2000 |
|
Director
of Analytical Services Operations, BioReliance Corporation,
Analytical Services.
- Managed
a $4 million department of 20-24 project managers,
technical writers, study directors and analytical
scientists to provide contract biomolecular analysis
for the characterization, stability and release testing
of over 200 bulk and formulated biotechnology products.
- Designed
and managed CMC analytical studies from pre-Phase
I through Phase III and commercialization.
- Supervised
divisional quality system programs to ensure top-down
GLP and cGMP compliance.
- Served
as the responsible divisional authority for quality
audits conducted by project sponsors, national and
international regulatory officials.
- Implemented
management systems to increase efficiency in resource
scheduling and facilities utilization.
- Developed
budgets, monitored profits and costs, and operated
laboratories and support functions at the highest
levels of responsiveness to meet timelines and deliverables
to clients.
- Successfully
recruited and retained highly skilled scientific staff
in a competitive technical location.
- Improved
and expanded testing services and optimized laboratory
growth to support new client projects.
|
| |
|
|
| 1996
to 1998 |
|
Senior
Scientist, Bulk Biomolecular Products, Abbott Diagnostics
Division, Analytical Development and Validation, Infectious
Diseases Sector R&D, Chicago, IL.
- Served
as a senior technical supervisor of $2.2 million analytical
R&D laboratory with 12 analysts developing and
validating analytical methods for well-characterized
biologicals used in CBER-regulated immunodiagnostic
products.
- Prepared
molecular biology, manufacturing, purification, analytical
characterization and lot release and stability sections
for 12 IND, 6 PLA/BLA submissions, 25 PMA submissions,
and 10 IPMF submissions to international regulatory
agencies.
- Acted
as divisional R&D representative in major technology
transfer projects of antibody and viral bulk products
from contract manufacturing operations.
- Directed
outsourced analytical studies though contract testing
organizations.
- Provided
expertise on Abbott test method and process validation
strategies at the division and corporate levels.
- Established
the Abbott "Quality Technical Reviewer"
model for approval of divisional analytical method
validations and method SOPS to provide greater technical
and quality expertise and increase efficiency.
- Served
as scientific specialist for two 40-member cGMP QC
operations teams that manufactured and tested over
100 biotechnology bulk products from US and international
plants.
|
| |
|
|
| 1992
to 1996 |
|
Senior
Research Biochemist, Biomolecular Products, Abbott
Diagnostics Division, Infectious Diseases Sector R&D,
Chicago, IL.
- Performed
analytical biochemistry of over 75 natural and rDNA
proteins, monoclonal and polyclonal antibodies, and
synthetic peptides using characterization techniques
such as HPLC, amino acid analysis, protein sequencing,
peptide mapping, SDS-PAGE, scanning densitometry,
IEF, immunoblots and assays, capillary electrophoresis,
light scattering, surface plasmon resonance and protein
identification via proteomic databases.
- Prepared
method SOPS, with transfer, training and troubleshooting
of methods to a 30-member QA laboratory.
- Established
ISO-9000 compliance activities in the department,
and served on corporate ISO certification task force.
- Certified
in the use of biohazardous and potentially biohazardous
viral materials, including BL3 biohazard suite access.
- Contributions
to over 125 analytical test method characterizations
and validations.
- Performed
direct supervision and review of 5 R&D laboratory
scientists.
|
| |
|
|
| 1988
to 1992 |
|
Postdoctoral
Research Fellow, University of Texas Dental Branch,
Department of Biological Chemistry, Houston, TX.
- Performed
biochemical characterization of the protein-protein
interactions between the bone protein osteopontin
and other bone extracellular matrix proteins.
- Techniques
included tissue culture, protein purification and
characterization, various ligand binding assays, in
vitro and in vivo radiolabelling of proteins, SDS-PAGE,
immunoblots, and glycoprotein analysis.
|
| |
|
|
| 1984
to 1988 |
|
Graduate
Fellow, Rice University, Department of Biochemistry
and Cell Biology.
- Conducted
molecular and cell biology studies of the subcellular
translocation of glutamine synthetase and other urea
cycle enzymes in shark and stingray tissues.
- Techniques
included DNA and RNA isolation, RIPA, nucleic acid
blots, subcellular fraction purification, kinetic
enzyme assays, immunohistochemistry, radiolabelled
pulse/chase assays, IEF and SDS-PAGE.
- Certified
in the use of beta and gamma radiation emitters.
|
| |
|
|
| 1980
to 1984 |
|
Senior
Research Assistant, University of Texas, Dental
Science Institute, Houston, TX.
- Purification
and comparative biochemical analysis of proteins from
microbial and animal models of biomineralization.
Techniques included microbial culture, lipoprotein
purification and characterization, in vitro mineralization
assays, and Xray diffractometry.
- Contributed
to cartilage extracellular matrix studies aboard Space
Shuttle missions for NASA.
|
| |
|
|
| 1978
to 1980 |
|
Research
Assistant, University of Texas, Dental Science Institute,
Houston, TX.
- Analytical
biochemistry of calcified cells and tissues for the
functional characterization of mineralizing proteolipids.
- Techniques
included microbial and tissue culture, protein concentration
and enzyme assays, and electron microscopy.
|
|
|
CONTINUING
EDUCATION
| 2000 |
|
Optimizing
Operational Performance, Dewitt, Boberg and
Associates Corporate Training Program, Rockville |
| 2000 |
|
Effective
Time Management, Dewitt, Boberg and Associates
Corporate Training Program, Rockville |
| 2000 |
|
Supervising
Technical Professionals, Dewitt, Boberg and
Associates Corporate Training Program, Rockville |
| 1997 |
|
Women
as Leaders National Workshop, Center for Creative
Leadership, NC |
| 1996 |
|
Finance
for Technical Managers, Professional Management
Course |
| 1996 |
|
Managing
Priorities, Professional Management Course,
Chicago |
| 1996 |
|
Application
of Statistics for Decision Making in Biopharmaceutical
Development, Technical Professional Course,
Chicago |
| 1995 |
|
Statistics
for Analytical Chemists, American Chemical Society
Course, Chicago |
| 1994 |
|
Leadership
of Technical Professionals, Professional Management
Workshop, Chicago |
| 1994 |
|
Equity
at Work, Professional Management Course, Chicago |
| 1994 |
|
Team
Leader Skills, Professional Management Workshop,
Chicago |
| 1994 |
|
Statistics
for Process Control, Technical Professional
Course, Chicago |
| 1993 |
|
The
New Manager: Supervising for Performance, Professional
Management Workshop, Chicago |
| 1993 |
|
Design
of Experiments, Technical Professional Course,
Chicago, |
HONORS
AND AWARDS
| 2002 |
|
Pharmaceutical
Training Institute Trainer of the Year |
| 2001 |
|
Pharmaceutical
Training Institute Trainer of the Month |
| 2000 |
|
BioPharm
Featured Ten Outstanding Women of Biotech |
| 1998 |
|
Abbott
Diagnostics Division R&D Technology Team Award
for Scientific Excellence |
| 1997 |
|
Abbott
Diagnostics Annual Outstanding Women Scientists
|
| 1997 |
|
Abbott
Corporate Chairman's Award for Individual Performance
Excellence |
| 1997 |
|
Abbott
Diagnostics Division Business Team Quality Award
|
| 1994 |
|
Abbott
Diagnostics Division Infectious Diseases R&D
Director's Award |
| 1992 |
|
American
Men and Women of Science |
| 1990 |
|
Outstanding
Young Investigator Award, Texas Society for Mineralized
Tissue |
| 1989 |
|
Outstanding
Graduate Student Award, Association for Women in
Science |
| 1984 |
|
Rice
University Graduate Fellowship |
| 1979 |
|
Outstanding
Young Women of America |
ORGANIZATIONAL
ACTIVITIES |
| Association
for Biomolecular Resource Facilities: Active participant
since 1994; member of the Education Committee, 1995-96
co-organized the 1995 Second Annual National Meeting in
Boston; member of the Quality and Compliance Committee
1996 - present, Committee Chairman 1997-1999. Co-founded
the Peptide Standards Project, a project sponsored by
the ABRF and funded in 2001 by NIST to product new traceable
biomolecular reference standards for cGMP analytical methods.
Serve as consultant to ABRF members on laboratory quality
practices and test method validations. |
|
The
Association for Women in Science: Active national
member since 1980; in Houston, assumed various chapter
Board positions over 12 years culminating in the Presidency,
1991-92. Contributed to a 250% growth in membership of
the local chapter, managed funded programs for graduate
scholarships, and career development workshops. Was an
invited participant on the national AWIS Task Force on
Diversity and the American Association of University Women
(AAUW) Texas Roundtable on Gender Issues in Education,
1992. Presented the 1993 Explorathon Career Week AWIS
keynote speech at the Cranbrook Institute of Science (Birmingham,
MI) along with Dr. Eugenie Clark, University of Maryland
marine biologist. Joined the Chicago AWIS chapter in 1993,
became a member of the Board in 1994, and President in
1996. Lead a 100% increase in membership and tripled the
chapter's activities, including establishing an ongoing
seminar series on leadership and career development in
the sciences.
|
|
| COMMITTEE
AND BOARD APPOINTMENTS: |
| 2005-2010 |
U.S.
Pharmacopeia, Nominated for Council of Experts in the
Biologics and Biotechnology Initiative Program for Biotechnology
and Natural Therapeutics/ Diagnostics |
| |
|
| 2005 |
California
Separations Sciences Society (CaSSS), " WCBP Workshop
Committee, Chair |
| |
|
| 2004 |
California
Separations Sciences Society (CaSSS), " WCBP Workshop
Committee, Co-Chair |
| |
|
| 2002-present |
California
Separations Sciences Society (CaSSS), CMC Strategy Forum
Co-Founder and Permanent Advisory Board Member |
| |
|
| 2002-present |
BioProcess
International: Editorial Board Member
|
| |
|
| 2001-present |
California
Separations Sciences Society (CaSSS), " Well-Characterized
Biotechnology Product (WCBP) Program Committee |
| |
|
| 2001-2003 |
Pharmaceutical
Training Institute: Scientific Advisory Board
|
| |
|
| 2001-present |
Association
for Biomolecular Resource Facilities (ABRF): ABRF-NIST
Peptide Standards Committee |
| |
|
| 2000-2002 |
BioProcessing
Journal (Williamsburg Bioprocessing Foundation): Editorial
Board Member |
| |
|
| 1996-1998 |
Association
for Biomolecular Resource Facilities (ABRF):
Cofounder and Chairman, Quality and Compliance Committee
|
| |
|
| 1994-1998 |
Association
for Women in Science, Chicago:President and Board Member |
| |
|
| 1984-1992 |
Association
for Women in Science, Houston:President and Board Member |
| |
|
CORPORATE
ACTIVITIES |
| 2000-2001 |
BioReliance,
Job Enrichment Action Team - Corporate task force to improve
career development opportunities |
| |
|
| |
BioReliance,
Human Resources Team - Corporate task force to improve
recruiting and retention activities |
| |
|
| 1999-2000 |
BioReliance,
Strategic Financial Team - Senior executive task force
to develop F&A metrics for operations |
| |
|
| 1997-1998 |
Abbott
Laboratories, Instructor, Corporate Quality College, "GMP's
in the Laboratory" |
| |
|
| |
Abbott
Laboratories, Divisional Representative for R&D, Corporate
Laboratory Council |
| |
|
| 1996-1997 |
Abbott
Laboratories, Divisional Task Force on Test Method Characterization
and Validation |
| |
|
| 1995-1996 |
Abbott
Laboratories, Divisional Task Force on ISO 9000 Documentation
and Quality Records |
| |
|
| 1993-1994 |
Abbott
Laboratories, Sector Task Force on R&D Career Development |
BIBLIOGRAPHY |
Chapters |
| 1. |
Ritter,
N.M. (editor) Biotechnological/Biological Product Stability
- Principles and Practices, in progress. |
|
|
| 2. |
N.
Ritter and J. McEntire, "Analytical Test Methods
for Biological and Biotechnological Products", in
Process Validation in Manufacturing of Biopharmaceuticals:
Guidelines, Current Practices, and Industrial Case Studies
(A.S. Rathore and G. Sofer, eds), CRC Press, Taylor and
Francis Group, Boca Raton, FL, 2005, pp. 227-326. |
|
|
| 3. |
Remmer,
H.A., Ambulos, N.P., Bonewald, L.F., Dougherty, J.D.,
Eisenstein, E., Fowler, E., Johnson, J., Khatri, A., Lively,
M.O., Ritter, N.M., and Weintraub, S. Synthetic Peptides
as Certified Analytical Standards, in Peptide Revolution:
Genomics, Proteomics and Therapeutics (Michael Chorev
and Tomi K. Sawyer, eds), American Peptide Society (2003). |
|
|
| 4. |
Calamai,
E.G., Krishnamurthy, R., McEntire, J., Pritchett, T.,
Ritter, N.M., Seely, R. J., Seaver, S., Venkat, K (coordinators/reviewers),
Guide to BioAnalytical Methods, BioPharm 14:12 (December,
2001). |
|
|
| 5. |
Ritter,
N., Smith, A., Fowler, B., Canova-Davis, E. Dougherty,
J., and Ghrist, B. Laboratory Quality and Compliance,
in The Encyclopedia of Bioprocess Technology: Fermentation,
Biocatalysis, and Bioseparation, Vol. 4 (Editors-In-Chief,
Michael C. Flickinger and Stephen W. Drew), John Wiley
& Sons, Inc., pp. 2113-2115 (1999). |
|
Peer-Reviewed Articles |
| 1. |
Ritter,
N.M., Advant, S., Simmerman, H., Advant, S., Hennessey,
J., McEntire, J., Joneckis, C, and Mire-Sluis, A. WCBP
CMC Strategy Forum: Industry and Regulatory Perspectives
on Analytical Test Method Qualification versus Validation
During Biotechnology Product Development, BioPharm (manuscript
under FDA review). |
|
|
| 2. |
Ritter,
N.M. and Hayes, T. Good Development Practice (GDP): Quality
Policies to Support Product Development Activities, BioProcessing
International, (manuscript in progress).
|
|
|
| 3. |
Ritter,
N. M. and McEntire, J. Determining Protein Concentration,
Part 2: Validation, BioPharm (manuscript in progress). |
|
|
| 4. |
Ritter,
N. M. and McEntire, J. Determining Protein Concentration,
Part 1: Methodology, BioPharm 15:4, 12-22 (April 2002). |
|
|
| 5. |
Ritter,
N.M. and Wiebe, M. Validating Critical Reagents Used in
cGMP Analytical Testing: Ensuring Method Integrity and
Reliable Assay Performance, BioPharm 14:5, 12-21 (May
2001). |
|
|
| 6. |
Ritter,
N. M. and Fowler, B. Analytical Laboratory Quality, Part
I - General Quality Practices, J. Biomolecular Techniques,
12:4-10 (2001). |
|
|
| 7. |
Ritter,
N.M., Hayes, T., and Dougherty, J. Analytical Laboratory
Quality, Part II - Analytical Method Validation, J. Biomolecular
Techniques 12:11-15 (2001). |
|
|
| 8. |
Smith,
A. and Ritter, N. Considerations in the Validation of
Bioanalytical Methods for Protein Characterization, Applied
Biosystems Reporter 22:1994, Applied Biosystems, Inc.
(1994). |
|
|
| 9. |
Ritter,
N.M., Farach-Carson, M.C. and Butler, WT. Evidence for
complex formation between osteopontin and osteocalcin,
J. Bone and Mineral Res. 7:877-885 (1992). |
|
|
| 10. |
D'Souza,RN.,Happonen,R.P.,Ritter,N.M.,
and Butler,W.T. Temporal and spatial patterns of TGF-beta
expression in developing rat molars, Arch. Oral Biol.
3 5:957-965 (1990). |
|
|
| 11. |
Ritter,
N.M., Smith, D.D., Jr., and Campbell, J.W. Glutamine synthetase
in liver and brain of the Holocephalan Hydrolagus collei,
J. Exp. Zool. 243:181-188 (1987). |
|
|
| 12. |
Smith,
D.D., Jr., Ritter, N.M. and Campbell, J.W. Glutamine synthetase
isozymes in elasmobranch brain and liver tissues, J. Biol.
Chem. 262:198-202 (1987). |
|
|
| 13. |
Goldschmidt,
M.C., Ritter, N.M. and Ennever, J.J. Age-dependency of
apatite formation in Bacterionema matruchotti, Microbios
Lett. 29:15-17 (1987). |
|
|
| 14. |
Boyan,B.D.and
Ritter,N.M. Proteolipid-lipid relationships in normal
and vitamin-D deficient chick cartilage, Calcified Tiss.
International 36:332-337 (1984). |
|
Invited Professional Presentations |
| 2003 |
| 1. |
USP
Conference on Biotechnology and Biological Products, "ABRF
Synthetic Peptides As Certified Analytical Standard Materials",
Crystal City, VA, November. |
|
|
|
CBI
5th Annual Stability Testing Program, full day workshop,
"Design of Stability Programs for Proteins, Biologics
and Macromolecular Systems", Philadelphia, PA, June. |
|
|
|
IBC
Conference on Bioassay Development and Validation, full
day workshop: "Regulatory Requirements and Quality
Practices for Bioassay Laboratories from R&D to GMP,"
Bethesda, MD, May. |
|
|
|
Plasma
Product Biotechnology Meeting: "Current CMC Requirements
for the Development of Plasma Products: What to do When"
Curacao, Netherland Antilles, April. |
|
|
|
Pharmaceutical
Training Institute: "How to Design and Execute Effective
Stability Programs for Biotechnology Products,"(12
national classes, repeated by request)
2002 |
|
|
| 2002 |
|
Pharmaceutical
Training Institute: "Conducting Laboratory Quality
Assurance Audits,"(class founder and instructor),
November - NC, December - Philadelphia |
|
|
|
University
of Maryland Graduate Program in Biopharmaceutical cGMP,
"Analytical Assay Development and Validation",
Spring and Fall semesters, Baltimore. MD |
|
|
|
AAI
Pharmaceutical Product Development Series: Stability Programs
for Global Submissions, "The Evolution of Stability
and Analytical Validation Requirements Throughout Product
Development", March, Clearwater Beach, FL |
|
|
|
IIR
East Coast Annual Symposium, Analytical and Bioanalytical
Methods Validation, chairperson and speaker, "Key
Issues to Consider in Analytical Methods OOS Investigations",
March, Philadelphia, PA |
|
|
|
Pharmaceutical
Training Institute: "How to Design and Execute Effective
Stability Programs for Biotechnology Products,"(12
national classes, repeated by request). |
|
|
|
Well-Characterized
Biotechnology Product (WCBP) Joint CaSSS/FDA 6th Symposium:
Interface of Regulatory and Analytical Sciences for Biotechnology
Health Products; workshop co-facilitator (with CBER and
CDER representatives) on "Transfer of Analytical
Methods: Down the Hall, Over the Wall and Across the Ocean,"
January, Washington DC |
|
|
| 2001 |
|
FDA
CBER Internal Training Program, Analytical Method Development
and Validation: "Assay Technology Transfer: From
R&D to QA, From Location to Location," December,
Rockville, MD. |
|
|
|
University
of the Sciences in Philadelphia, Cantor Series lecturer,
"Biotechnology Drugs: Stability and Regulatory Issues,"
November, Philadelphia, PA |
|
|
|
Williamsburg
Bioprocessing Foundation Symposium: Raw Materials and
Contract Services for Mammalian Cell Products, "Qualification
of Critical Reagents Used in Analytical Laboratories,"
July, Newport Beach, CA. |
|
|
|
IBC
4th International Conference: Well-Characterized Biologicals:
Managing Pre-and Post-Approval Manufacturing Changes,
(with Heather Simmerman, Amgen) "Method Qualification
vs Method Validation: How Do You Define a Method's Intended
Use?" June, Seattle |
|
|
|
Institute
for Validation Technology Conference: Investigation of
Out-of-Specification Test Results, "Developing Effective
Communications Between the Contract Testing Facility and
Manufacturer: Who's On First?," April -Washington
DC and May - London |
|
|
| 2000 |
|
Institute
for Validation Technology Conference: Laboratory Equipment
Qualification and Validation, "What SOP? Adventures
in Laboratory Training." April - Washington DC and
May - London. |
|
|
|
IBC
International Conference: Formulation Strategies for Biopharmaceuticals
Conference Co-founder, Co-organizer, and session chairperson,
March, San Diego, CA. |
|
|
|
Pharmaceutical
Training Institute: "How to Design and Execute Effective
Stability Programs for Biotechnology Products," class
founder and speaker (6 national classes). |
|
|
|
Williamsburg
Bioprocessing Foundation Conference: Adenoviral Vector
Testing: Product Characterization, and Methods Standardization,
session chair and speaker, "Developing Guidelines
and Standards for Analytical Assays," October, Washington,
DC. |
|
|
|
Williamsburg
Bioprocessing Foundation Conference: Raw Materials and
Contract
Services for Mammalian Cell Products, "Perspectives
on Assuring the
Quality of Materials and Reagents Used by cGMP Analytical
Laboratories," June, St.Louis, MO |
|
| 1999 |
|
Cambridge
Healthtech Institute Conference: Biological Safety Issues,
session chair and speaker, "Overview of Current Analytical
Techniques for Contaminants and Impurities in Biotechnology
Products," October, Washington, DC. |
|
|
|
Biotechnical
Institute of Maryland, developed training class on "GMP
Laboratory Compliance", Spring, Baltimore, MD. |
|
|
| 1997 |
|
National
Medical Health Consortium Biotechnology Conference: Technologies
for
Characterization of Drug Candidates, invited speaker,
"Accessing Technologies via
Analytical Laboratories: Evaluation of Laboratory Quality
Practices," Washington,DC |
|
|
| 1995 |
|
Association
of Biomolecular Resource Facilities (ABRF) 2nd Annual
National Meeting,
"Compliance Activities in Academic Core Facilities,"
Boston, MA. |
|
|
| 1994 |
|
Characterizing
Expressed Proteins: Structural Analysis of Recombinant
Proteins Seminar Series,"Validation Strategies and
Compliance Issues in Protein Sequencing and Amino Acid
Analysis," San Diego and San Francisco, CA. |
|
|
| Juried
Poster Presentations |
|
Spirakes,
T., Steffens, M., Schmidt, D., Lang, E., Singh, K.,
Nguyen, C., Ritter, N., and Watanabe, S. Monoclonal
Antibody Characterization. ADD Technology Exchange (1998).
|
|
| Ritter,
N. Generic Characterization and Validation of Western
Blot Tests, Abbott Corporate Technology Exchange (1997). |
|
| Ritter,
N., Gunasekera, A., Adarnczyk, M. and Smith, D. Patient
Sera Recognition of Synthetic Peptides via Surface Plasmon
Resonance, Abbott Corporate Technology Exchange (1997). |
|
| Ritter,
N., Baharani, S., Gao, Y., Falcon, R., Snyder, S. and
Matayoshi, E. Synthetic Peptide Viscosity Characterization,
ADD Technology Exchange (1996). |
|
| Ritter,
N., Gao, Y., Wilson, M., Ownby, D., Qui, P., Bustamante,
P., and Kundu, S. Viral Protein Characterization and Associated
Impurities, ADD Technology Exchange (1996) |
|
| Ritter,
N., Grant, D., Baharani, S., Dorsey, T., Gracey, D., Ho,
I., and Green, P. Evaluation of an Outsourced Viral Preparation
for Use in Diagnostic Assays, ADD Technology Exchange
(1996) |
|
| Ritter,
N., Lopez, M., and Kundu, S. Evaluation of Scanning Densitometers
for Quantitative SDS-PAGE of Proteins, Abbott Corporate
Technology Exchange (1995). |
|
| Ritter,
N., Baharani, S., Schmidt, D., Wilson, M., Tarpey, L.,
Smith, A., Hoff, J., Lund, J., Nfikolajczak, D., Raymo,
P., Zurbuch, D., and Bohrer, N. N-Terminal Amino Acid
Sequencing, Peptide Mapping, and Isoelectric Focusing
Validation Strategies for Proteins in FDA-CBER Products,
ADD Technology Exchange (1994). |
|
| Walter,
P., Junge, J., Gao,Y., Hoff, J., Gershon, B., and Ritter,
N. Characterization of Rare Reagents for FDA-CBER Submissions,
ADD Technology Exchange (1994). |
|
| Avenetti,
K., Walter, P., Ritter, N., Ali, A. and Smith, D. HPLC
gel permeation chromatography of recombinant proteins,
Abbott Corporate Technology Exchange (1993). |
|
| Ritter,
N.M., Farach-Carson, M.C. and Butler, W.T. Osteopontin
binding to extracellular matrix proteins, Conn. Tiss.
Res. 27:121 (1992). |
|
| Ritter,
N.M., Farach-Carson, M.C. and Butler, W.T. In vitro complex
formation between osteopontin and osteocalcin. J.Bone
and Mineral.Res.6:304 (1991). |
|
| Sampson,
H.W., Vogel, J.J., Ritter, N.M. and Hakim, F. Changes
in sphingomyelin and non-collagenous proteins during intervertebral
disk mineralization in progressive ankylosis mice, Conference
on Cell-Mediated Calcification and Matrix Vesicles, Hilton
Head, S.C. (1991). |
|
| D'Souza,
R.N., Ritter, N.M., Edwards, D.K. and Butler, W.T. Temporal-spatial
patterns of TGF-I expression in rat molar odontogenesis,
J. Dent. Res. 69:121 (1990). |
|
| Ritter,
N.M., Fujisawa, R.T., Farach-Carson, M.C. and Butler,
W.T. Osteopontin-binding proteins from demineralized bone
matrix and osteosarcoma cells, J. Cell Biol. 109:199a
(1989). |
|
| Ritter,
N.M., Smith, D.D., Jr. and Campbell, J.W. Glutamine synthetase
isozymes and evolution of Chondrichthyes, Fed. Proc. 46:2275
(1987). |
|
| Ritter,
N.M., Smith, D.D., Jr. and Campbell, J.W. Elasmobranch
brain glutamine synthetase, Fed. Proc. 45:1734 (1986). |
|
| Ritter,
N.M. and Boyan, B.D. A comparison of proteolipid concentration
and calcification in normal and rachitic epiphyseal cartilage,
Fed. Proc. 39:661 (1980). |
Page
Updated:
July 25, 2007
|